Sarecycline

Sarecycline
Clinical data
Trade names	Seysara
Identifiers
	IUPAC name (4S,4aS,5aR,12aR)-4-(Dimethylamino)-1,10,11,12a-tetrahydroxy-7-[[methoxy(methyl)amino]methyl]-3,12-dioxo-4a,5,5a,6-tetrahydro-4H-tetracene-2-carboxamide;
CAS Number	1035654-66-0;
PubChem CID	71296095;
ChemSpider	28540486;
UNII	94O110CX2E;
Chemical and physical data
Formula	C24H29N3O8
Molar mass	487.51 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)CN(C)OC;

Sarecycline (trade name Seysara; development code WC-3035) is a tetracycline-derived antibiotic. In the United States, it was approved by the FDA in October 2018 for the treatment of moderate to severe acne vulgaris.^[1]

Paratek Pharmaceuticals, Inc. licensed the US rights to sarecycline for the treatment of acne in the United States to Actavis, a subsidiary of Allergan, while retaining rights in the rest of the world.^[2]

Allergan initiated a Phase 3 study in December 2014 evaluating the efficacy and safety of sarecycline tablets 1.5 mg/kg per day taken orally for 12 weeks versus placebo in the treatment of acne vulgaris.^[3] Two phase 3 randomized, multi-center, double-blind, placebo-controlled studies evaluating the efficacy and safety of sarecycline in moderate to severe acne reported positive results on 27 March 2017.^[4]

References

↑ "FDA Approves Sarecycline for Moderate to Severe Acne". MedScape. October 2, 2018.
↑ https://www.bloomberg.com/research/stocks/snapshot/snapshot_article.asp?ticker=N4CN:GR&txtsize=s
↑ "Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne - Full Text View - ClinicalTrials.gov".
↑ "Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne". www.globenewswire.com. Retrieved 16 May 2017.

External links

Sarecycline - Almirall S.A./Paratek Pharmaceuticals, Adis Insight

This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.

[1] "FDA Approves Sarecycline for Moderate to Severe Acne". MedScape. October 2, 2018.

[2] ttps://www.bloomberg.com/research/stocks/snapshot/snapshot_article.asp?ticker=N4CN:GR&txtsize=s

[3] "Study to Evaluate Safety & Efficacy of Sarecycline in Treatment of Acne - Full Text View - ClinicalTrials.gov".

[4] "Allergan and Paratek Announce Positive Results From Two Phase 3 Trials of Sarecycline for the Treatment of Moderate to Severe Acne". www.globenewswire.com. Retrieved 16 May 2017.